Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert; Evan Atlantis; Mathis Grossmann; Bu B. Yeap; Ann Conway; Bronwyn Stuckey; David Handelsman; Robert McLachlan; Carolyn Allan; Alicia Jenkins; Mark Daniel; Karen Bracken

Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert, Evan Atlantis, Mathis Grossmann, Bu B. Yeap, Ann Conway, Bronwyn Stuckey, David Handelsman, Robert McLachlan, Carolyn Allan, Alicia Jenkins, Mark Daniel, Karen Bracken

Health Research Institute

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

Original language	English
Pages (from-to)	47-48
Number of pages	2
Journal	Clinical Endocrinology
Volume	89
Issue number	S1
Publication status	Published - Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727

Cite this

Wittert, G., Atlantis, E., Grossmann, M., Yeap, B. B., Conway, A., Stuckey, B., Handelsman, D., McLachlan, R., Allan, C., Jenkins, A., Daniel, M., & Bracken, K. (2018). Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. Clinical Endocrinology, 89(S1), 47-48. https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727

@article{2373be95ba694f059b9dc4b2506b04d4,

title = "Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial",

abstract = "Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers{\textregistered}) as compared to lifestyle intervention alone, reduces T2D at 2 years.",

author = "Gary Wittert and Evan Atlantis and Mathis Grossmann and Yeap, {Bu B.} and Ann Conway and Bronwyn Stuckey and David Handelsman and Robert McLachlan and Carolyn Allan and Alicia Jenkins and Mark Daniel and Karen Bracken",

year = "2018",

month = jun,

language = "English",

volume = "89",

pages = "47--48",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell",

number = "S1",

}

Wittert, G, Atlantis, E, Grossmann, M, Yeap, BB, Conway, A, Stuckey, B, Handelsman, D, McLachlan, R, Allan, C, Jenkins, A, Daniel, M & Bracken, K 2018, 'Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial', Clinical Endocrinology, vol. 89, no. S1, pp. 47-48. <https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13727>

TY - JOUR

T1 - Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

AU - Wittert, Gary

AU - Atlantis, Evan

AU - Grossmann, Mathis

AU - Yeap, Bu B.

AU - Conway, Ann

AU - Stuckey, Bronwyn

AU - Handelsman, David

AU - McLachlan, Robert

AU - Allan, Carolyn

AU - Jenkins, Alicia

AU - Daniel, Mark

AU - Bracken, Karen

PY - 2018/6

Y1 - 2018/6

N2 - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

AB - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

M3 - Meeting Abstract

SN - 0300-0664

VL - 89

SP - 47

EP - 48

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - S1

ER -